How THC and CBD Affect Sleep: A Controlled Study with Brain Wave Monitoring ↗
Sleep study finding 15 mg THC was sedating while 15 mg CBD had alerting properties and counteracted THC sedation, with EEG showing CBD increased wakefulness during sleep.
Explore published research on sleep, including study methods and limitations.
Sleep study finding 15 mg THC was sedating while 15 mg CBD had alerting properties and counteracted THC sedation, with EEG showing CBD increased wakefulness during sleep.
Randomized trial of 66 MS patients found THC:CBD spray significantly reduced central neuropathic pain (P = 0.005) and sleep disturbance (P = 0.003) with 97% completion rate.
Clinical case series of 20 chronic pain patients found 75% reported improvement with nabilone, with sleep and nausea benefits being the primary reasons for continued use.
In the first 48 hours after stopping heavy cannabis use, lab sleep was shorter, lighter, and more fragmented, with bigger gaps versus controls on night two.
Review found cannabis acutely helps sleep onset and deepens sleep but withdrawal causes insomnia and vivid dreams, while cocaine and ecstasy primarily disrupt sleep through arousal.
Heavy teen marijuana use was linked to modest cognitive disadvantages, subtle brain differences, and poorer sleep. Some changes persisted past a month and sometimes resolved by three months of abstinence.
Crossover RCT of 29 fibromyalgia patients found nabilone improved sleep quality more than amitriptyline, though neither affected pain in two-week treatment periods.
The Cannabis Withdrawal Scale was developed with excellent reliability, revealing nightmares as the most diagnostic symptom and angry outbursts as the most distressing.
Fibromyalgia cannabis users reported significant pain and stiffness relief within 2 hours and better mental health scores compared to non-users.
Three nights off cannabis cut sleep efficiency and total sleep time and shifted REM. Extended-release zolpidem restored efficiency but did not shorten time to fall asleep.
Objective measurement of cannabis smoking showed front-loaded puffing and dose-dependent prediction of withdrawal severity, especially sleep disruption.
Phase III trial found oral cannabis extract nearly doubled muscle stiffness relief compared to placebo in 279 MS patients, with benefits for pain and sleep.
Systematic review of 34 human studies found preliminary CBD benefits for anxiety, insomnia, and epilepsy, with complex THC interactions depending on delivery route.
Veterans with poor perceived sleep quality reduced their cannabis use less during a 6-month quit attempt, even after accounting for PTSD and withdrawal.
Quetiapine improved sleep and appetite during cannabis withdrawal but increased craving and use during the relapse phase, disqualifying it as a dependence treatment.
In 76 adults with ADHD, marijuana use correlated with inattention in men and poor sleep quality in women, suggesting sex-specific effects.
Review found sleep disturbance and substance use disorders reinforce each other, with cannabis withdrawal showing objective sleep disruption and insomnia treatment identified as a gap.
Systematic review of 39 human studies found mixed cannabinoid effects on sleep and study quality too uneven for clear answers.
During monitored cannabis abstinence, most withdrawal symptoms peaked in days 0-3 and improved, but sleep disturbance and strange dreams got progressively worse over time.
RCT of 246 neuropathic pain patients found THC/CBD spray achieved significant 30% pain response rates (p=0.034) and improved sleep quality versus placebo.
A survey of 225 Canadian MS patients found 19.5% currently use cannabis (mainly for sleep, pain, anxiety, spasticity), with half saying they would use if legal.
A systematic review of 36 human studies confirmed that sleep disruption is a consistent feature of cannabis withdrawal, but methodological differences between studies prevented clear conclusions about which specific aspects of sleep are most affected.
An inpatient study found that combining the sleep aid zolpidem with the synthetic THC pill nabilone reduced cannabis withdrawal symptoms and decreased cannabis self-administration more than zolpidem alone.
Animal research shows the endocannabinoid system stabilizes NREM sleep bouts but does not drive the homeostatic need to sleep, helping explain cannabis's complex effects on sleep.
Review of cannabis and sleep research through 2017 found CBD promising for insomnia, THC mixed (faster onset but worse quality), and the whole field still in its infancy.
Survey of 47 Parkinson's patients found large self-reported improvements in falls, pain, and tremor with medical cannabis, but 17% experienced confusion or hallucinations.
Dispensary study of 217 patients finding younger medical cannabis users consume more and show more problematic use than older users, with early initiation as a key risk factor.
Study of 302 adults finding that reducing cannabis use over 12 weeks improved anxiety, depression, and sleep quality but not overall quality of life, with effects independent of other substance use changes.
Review proposing that the endocannabinoid system influences dream activity, supported by its known roles in consciousness, emotion, and sleep, and by preliminary evidence of cannabinoid-related nightmare reduction in PTSD.
Rat study showing AA-5-HT (dual FAAH/TRPV1 blocker) promoted sleep during active periods, restored sleep after deprivation, and blocked the wake-promoting effects of CBD and modafinil.
Review arguing that cannabis and stimulant drugs damage well-being through the same core mechanism: cyclical mood disruptions that chronically stress the body's hormonal and neurological systems.
Survey of 1,513 medical cannabis patients found over 75% reduced opioid use and 65-72% reduced sleep and anxiety medications, though their primary care doctors often did not know.
The biology linking the endocannabinoid system to PTSD was strong, but clinical evidence for cannabis as treatment was weak. Nabilone showed real promise for nightmares specifically.
Israeli survey of 383 fibromyalgia patients found 84% used cannabis with 94% reporting pain relief, though only 44% were medically licensed and most smoked rather than using other methods.
Small study of 26 fibromyalgia patients found all improved on every measure after medical cannabis, with 50% stopping all other medications and only mild adverse effects in 30%.
Colorado survey found 70% of SCI/TBI patients used cannabis before injury and 48% after, with spasticity reduction (SCI) and recreation/stress relief (TBI) as primary reasons.
Survey of 455 medical cannabis patients found 1,987 strains available, with preferences highly dispensary-specific and many patients using sativa by day and indica at night.
Cancer patients in Minnesota's medical cannabis program reported significant improvement across all 8 tracked symptoms, with 27-50% achieving lasting clinically meaningful reductions and only 10.5% reporting side effects.
A survey of 1,000 Colorado recreational dispensary customers found 65% used cannabis for pain and 74% for sleep, with most reporting they reduced or stopped using other medications including opioids.
Colorado grocery store data shows OTC sleep aid sales dropped sharply after recreational dispensaries opened, with a 236% trend reversal driven by substitution away from antihistamine-based sleep products.
Largest MS cannabis survey finds 49% of 2,009 Danish patients have used cannabis, mostly illegally, reporting high efficacy for pain and spasticity with mild side effects, while 44% of non-users would consider it if legalized.
Rats showed more NREM sleep only for 1 hour after the highest vaporized THC dose, only in the light phase.
Systematic review of cannabis for PTSD through 2019 found promising signals for nabilone and nightmares, but most evidence remained low-quality and the broader case unproven.
Observational study of 102 fibromyalgia patients found adding medical cannabis improved sleep in 44%, overall symptoms in 33%, and allowed 47% to reduce other pain medications over 6 months.
Systematic review of 10 studies found cannabinoids may reduce PTSD symptoms, especially sleep disturbances and nightmares, but all evidence was of low quality with only one controlled trial.
Six-week RCT of 65 overweight adults found 15mg daily CBD hemp extract significantly improved HDL cholesterol, with trends toward better sleep and stress coping.
Rats exposed to cannabinoid agonist during adolescence showed persistent sleep disruption in adulthood, with decreased wakefulness and increased REM sleep.
Review found preclinical evidence for CBD benefits relevant to athletes (pain, inflammation, anxiety), but no studies have directly tested CBD in athletic populations.
First clinically-focused systematic review found CBD tentatively supported for social anxiety and adjunctive schizophrenia, with high-THC showing no depression benefit.
Systematic review of 26 studies found insufficient evidence for cannabinoids as routine sleep treatments but promising leads for sleep apnea, insomnia, and PTSD nightmares.
Among nearly 12,000 children in the ABCD Study, prenatal cannabis exposure was associated with multiple sleep disturbances at ages 9-10, even after controlling for other prenatal exposures.
The first 129 patients in the UK Medical Cannabis Registry showed significant improvements in anxiety, sleep, pain, and quality of life at 1 and 3 months, with 24% reporting adverse events.
Daily diary study of 62 cannabis users found those with more ADHD symptoms experienced more daily cannabis consequences, with boredom and sleep motives increasing problems further.
Survey of 319 rheumatology patients found self-reported pain reductions of 57-83% and sleep improvements of 71-87% with medical cannabis, with neuropathic pain patients reporting the greatest benefit.
Prospective study of 35 children with drug-resistant epilepsy found CBD cut abnormal brain discharges nearly in half and improved sleep microstructure in 85% of those with initial sleep abnormalities.
A randomized trial found daily moderate-intensity cycling during inpatient cannabis withdrawal improved objective sleep duration and efficiency compared to stretching, though participants did not perceive the difference.
Review of whole-plant cannabis and sleep found effects depend on dose, strain, and delivery — with vaporized high-THC cannabis promoting deep sleep in animals.
Prospective study of 28 MS patients finds low-dose cannabis oils (4 mg THC, 7 mg CBD) significantly reduce pain, spasticity, and sleep problems without impairing function.
Prospective study of 361 veterans found sleep problems drove ADHD-related cannabis use, while using cannabis to cope with negative emotions predicted cannabis-related problems.
Prospective study of 46 adults using real-time smartphone assessments found medical cannabis reduced pain intensity, anxiety, depression, and improved sleep over 3 months.
Survey of 568 adults 65+ found 15% used cannabis, with most starting after 60 for medical purposes (mainly pain), yet only 41% told their healthcare provider.
A survey of 258 menopausal women found 79% using cannabis for symptoms, most commonly sleep and anxiety, with perimenopausal women reporting worse symptoms and more anxiety-motivated use.
UK registry data showed 74 ASD patients had significant improvements in quality of life, sleep, and anxiety after starting cannabis-based medicines.
Pilot study showed CBT for insomnia resolved sleep problems in cannabis users, with 80% reducing cannabis use at 3 months and sustained improvements in mood.
THC withdrawal in mice disrupted dopamine release, sleep patterns, and behavior in ways that mirror human withdrawal, with more pronounced effects in males.
Cannabis products showed minimal to no benefit for sleep disorders in this review, and cannabis withdrawal itself causes significant insomnia that can drive relapse.
Despite widespread use, clinical evidence doesn't yet support cannabis as a reliable treatment for insomnia, sleep apnea, or other specific sleep disorders — but early results are promising.
In young adult binge drinkers with insomnia, cannabis use during CBT-I treatment did not reduce therapy effectiveness, with virtually zero moderation effect on outcomes.
In a cannabis dependence trial, depression, anxiety, insomnia, and pain all improved over 12 weeks regardless of medication type, and even without complete abstinence from cannabis.
Small pilot study of 20 patients found a CBD-melatonin sublingual compound improved sleep quality, reduced anxiety, and decreased pain over 3 months, but lacked a control group.
First CBG patient survey found users reported it effective for anxiety (51%), pain (41%), and depression (33%), with 74-80% rating it superior to conventional medications and 44% reporting no side effects.
Survey of 344 Canadian MS patients found 65% had tried medical cannabis, primarily for sleep (84%), pain (80%), and spasticity (68%). 74% learned about it outside the healthcare system.
Placebo-controlled trial of 150 children with autism found CBD-rich cannabis treatment was not better than placebo for any aspect of sleep.
Study of 79 young people found cannabis withdrawal symptoms peaked in the first week of monitored abstinence then declined, with mood and sleep most affected.
Australian registry of 3,961 patients found medicinal cannabis was safe and showed sustained improvements in pain, mental health, and insomnia over 2+ years.
Review found CBD therapeutic effects emerge at 300+ mg/day, with best evidence for anxiety and addiction. Most OTC products fall below this threshold.
Mouse study found cannabinoid cessation reduced sleep during normal sleep periods, providing an animal model for human cannabis withdrawal sleep disturbance.
RCT found adolescents who quit cannabis experienced trouble falling asleep during the first week, but sleep returned to normal by week two and stayed there through week four.
MASCC systematic review of 15 RCTs found no high-quality evidence for cannabis treating anxiety, depression, or insomnia in cancer, though sleep showed some promise.
Geriatrics clinic survey found elderly cannabis users treating sleep problems prefer THC over CBD, use daily, and take it right before bed — often without clinician guidance.
After one month, 63% of new medical cannabis patients reported effective pain relief, plus reduced medication use, less anxiety, and better sleep — though finding the right product was a common struggle.
Placebo-controlled crossover trial found THC/CBD cannabis oil helped 60% of insomnia patients no longer qualify as clinical insomniacs, with increased melatonin and sleep duration.
CBD extended sleep in rats but disrupted sleep oscillations critical for memory, impairing complex memory consolidation while leaving simple memory intact.
Women increasingly use cannabis for endometriosis, pelvic pain, and period cramps, with retrospective data suggesting benefit — but clinical trials are nearly nonexistent and barriers to medical access persist.
12-month study of 323 fibromyalgia patients found medical cannabis reduced pain partly through improvements in sleep and anxiety/depression symptoms.
ABCD Study analysis of ~10,000 children found sleep protects against behavior problems, but prenatal cannabis exposure significantly weakened this protective effect.
Mouse study found a hemoglobin-derived peptide promoted deep sleep through CB1 cannabinoid receptors, revealing new endocannabinoid sleep regulation pathways.
Study found youth with more sleep trouble used more cannabis overall, but on specific bad-sleep nights, they were actually less likely to use the next day.
Longitudinal study of 1,105 veterans found a self-reinforcing cycle: insomnia increased stress, stress increased cannabis use, and cannabis use worsened both stress and insomnia, challenging its use as a sleep or stress remedy.
A national birth cohort study found later bedtimes and shorter sleep in childhood predicted higher odds of trying marijuana by age 15.
Survey of 550 opioid addiction patients found 23% use CBD — primarily for anxiety, pain, and sleep, with 42% using it specifically for withdrawal relief.
A 12-week RCT found zolpidem prevented early cannabis withdrawal sleep disturbance but did not significantly increase quit rates (27% vs 15%), with sleep problems returning after medication stopped.
College drinkers with ADHD had worse sleep and more alcohol-related consequences, but ADHD did not increase cannabis-related negative outcomes.
Cannabis users showed reduced demand when imagining driving but increased demand in sleep contexts with cannabis cues, suggesting safety concerns can override drug motivation.
Evening chronotype and cannabis use disorder independently predicted earlier bipolar mood symptom onset, suggesting circadian rhythm disruption may underlie both conditions.
National Canadian survey finds 15.6% of adults use cannabis for sleep, surpassing prescription medication use, with young men most likely to choose cannabis.
UK registry data from 141 MS patients found prescribed cannabis products improved quality of life across cognitive, physical, emotional, and social domains over six months.
Mayo Clinic survey of 1,336 fibromyalgia patients found nearly half used cannabis, primarily for pain (82% reported improvement), fatigue, anxiety, and insomnia.
Crossover trial found no meaningful next-day impairment in cognition, psychomotor function, or simulated driving after adults with insomnia took 10mg THC + 200mg CBD oil the previous evening.
UK registry data from 124 insomnia patients showed medical cannabis improved sleep quality significantly, with benefits persisting but declining over 18 months.
Survey of 80 Canadians with spinal cord injury found 42.5% used cannabis post-injury, shifting from recreational to pain and sleep motivations with edibles as preferred method.
Survey of 413 women found younger women substituted THC for alcohol driven by sleep problems (OR 5.82), while older women substituted less and were driven by PTSD symptoms.
In-home EEG study of 339 nights found cannabis use altered multiple sleep stages, but effects on deep sleep and REM differed significantly depending on whether the person had chronic pain.
In a 30-person crossover RCT, THC-related simulator crashes peaked 4 hours after inhalation.
Meta-analysis of 6 RCTs (1,077 patients): cannabinoids improve sleep quality, but the effect is driven by non-CBD formulations. CBD alone showed no benefit.
1,139 UK chronic pain patients on medical cannabis: those with sleep problems showed greater pain improvements over 12 months than those without.
3-month daily diary study of 74 veterans: cannabis use predicted lower next-day stress, which predicted fewer PTSD symptoms and better sleep quality.
Veterans daily diary: cannabis linked to same-day lower stress and better sleep with no next-day effects. Poor sleep drives next-day stress and alcohol use.
A systematic review of 49 controlled studies across 11 mental health diagnoses found CBD may offer short-term anxiety relief and CBD/THC combinations helped with cannabis withdrawal and sleep, but THC worsened psychosis and no long-lasting benefits were found for any product.
A national US longitudinal study found alcohol and cannabis problems initially predicted fewer sleep issues but later predicted more, while people who used both consistently slept worse than the general population, suggesting a reversing relationship over time.
Among people misusing prescription sleep aids, 55.5% also used marijuana, with two profiles: a common alcohol/marijuana/tobacco pattern and a riskier polysubstance pattern.
Survey found nearly half of breast cancer patients used CBD, mainly for pain and insomnia, with mixed self-reported results.
Small crossover trial found a low-dose cannabinoid supplement (3 mg THC, 6 mg CBN, 10 mg CBD) improved sleep quality and insomnia symptoms vs placebo over 10 days.
Secret shopper study of 35 Bay Area dispensaries found budtenders consistently recommended topicals for pain and edibles for sleep, based on personal experience.
A German survey of 702 CBD users found 38% self-medicate for sleep, pain, depression, and anxiety, with older and unemployed individuals most likely.
Adults with opioid addiction and chronic pain who added a daily THC:CBD capsule to their buprenorphine treatment reported less pain and better sleep after three months, though opioid cravings did not significantly change.
Year-long interviews with people on opioid addiction treatment found they reported less pain, better mood and sleep, and fewer drug cravings from medical cannabis, though cost and appetite changes were concerns.
A study of people with anxiety found that baseline inflammation levels influenced whether different cannabis products improved mood and sleep, with CBD-dominant products showing the most reliable benefits.
Meta-analysis of 120 studies found recreational cannabis use was linked to worse sleep in observational research, but experimental studies showed no effect, suggesting the relationship is more complex than it appears.
A crossover RCT of 20 healthy adults found that low-dose THC:CBD oils (1:1 and 1:16 ratios) did not cause daytime sleepiness or change night-time sleep compared to placebo.
Among multiple cannabinoid treatments tested in sleep-deprived mice, a CBD+CBC combination was the most effective at reversing memory impairment, depression, and brain inflammation.
Among 1,466 cannabis users with chronic conditions during COVID-19, 91% used cannabis medicinally for sleep, pain, and headaches, but most lacked medical guidance.
Twin study of 3,165 adults found cannabis use for sleep linked to worse sleep quality and more substance use, even after controlling for shared genetics.
Daily tracking of 65 young people in cannabis treatment showed cannabis helped sleep in the first two weeks but the benefit disappeared by week three.
Clinician survey found over half of opioid treatment clients reportedly use cannabis, with recognized benefits for sleep and mental health alongside harms like dependence.
Analysis of 25,000 relevant tweets found mostly positive public sentiment about CBD for insomnia, though clinical trial evidence remains limited.
Scoping review of 29 studies found CBD shows promise for both anxiety and sleep, but inconsistent methods and dosing across studies limit definitive conclusions.
Among 1,962 cancer patients in Minnesota's medical cannabis program, higher CBD doses were linked to better sleep improvement (1.87 points on 0-10 scale), while THC showed no consistent sleep benefit.
12-month observational study of 137 new medical cannabis patients found early and sustained improvements in self-reported sleep quality across all measures, regardless of administration route or condition.
Large prospective study of 2,449 trauma survivors found pre-trauma insomnia predicted heavier cannabis and alcohol use 8 weeks later, partly through early PTSD symptoms.
A meta-analysis of polysomnographic studies found cannabis doesn't consistently change measurable sleep patterns, but quitting after regular use clearly disrupts sleep — highlighting a gap between subjective and objective sleep effects.
Among 1,322 Canadian adults with type 1 diabetes, cannabis users had 58% higher odds of poor sleep quality — notable given that nearly half of T1D adults already sleep poorly.
People with hypersomnolence disorders used cannabis at nearly double the general population rate in the Netherlands, with most current users reporting symptom improvement — providing rationale for clinical trials.
A double-blind RCT found that CBD gel applied to jaw muscles nightly for 30 days significantly improved sleep quality and reduced migraine disability in bruxism patients, with 10% CBD showing the strongest effects.
Analysis of 175,493 Americans showing recreational cannabis legalization is associated with falling asleep 7 minutes later and sleeping 5 minutes less per night.
Survey of 2,602 cancer patients finds 1 in 4 use cannabis — primarily for sleep, with higher use among Stage 4 and chemotherapy patients, using multiple consumption methods.
A pilot study found that THC before bedtime increased sleep onset time and slow-wave sleep but significantly reduced heart rate variability during sleep, suggesting cardiovascular effects of nighttime cannabis use.
A randomized trial found 300 mg CBD improved sleep more than 50 mg CBD in high-worry individuals, but the difference from placebo was not statistically significant after 2 weeks of daily use.
First rigorous clinical trial of CBN for insomnia shows 300 mg improved subjective sleep quality and time to fall asleep but missed the primary endpoint of reducing nighttime wakefulness.
Pilot study tracking daily cannabis use motives over 28 days finds shifts toward sleep-aid and availability motives predict higher use, demonstrating feasibility of adaptive just-in-time interventions.
Daily diary study finds young adults report better sleep quality on days they use alcohol and cannabis together versus alcohol-only or no-use days.
Medical cannabis improved sleep, fatigue, and pain for spasticity/spasm patients but not physical functioning.
RCT with 60 chronic insomnia patients found cannabis oil matched lorazepam for sleep improvement over 4 weeks, with better quality-of-life outcomes and only mild side effects.
Qualitative study found veterans in addiction treatment used cannabis to manage chronic pain, anxiety, and sleep — framing it as a harm reduction alternative to more dangerous substances.
RCT found THC/CBD reduced total sleep time by 25 minutes and dramatically cut REM sleep by 34 minutes in insomnia patients — challenging the cannabis-aids-sleep belief.
UK registry data from 497 fibromyalgia patients showed medical cannabis was linked to improved pain, anxiety, sleep, and quality of life, though nearly half reported side effects.
Canadian 24-week study found medical cannabis patients improved on pain, anxiety, depression, and quality of life measures, but improvements fell below clinically meaningful thresholds.
Pilot RCT of 32 pancreatic cancer patients found medical cannabis feasible through state program partnership, with promising but non-significant improvements in pain, appetite, and insomnia.
Nabilone significantly reduced PTSD nightmares in 10 treatment-resistant military veterans, leading the Canadian Armed Forces to adopt cannabinoids for PTSD treatment.
Zero clinical trials support CBN as a sleep aid. Eight human studies found no reliable sedative effects. The "sleepy cannabinoid" label is marketing, not science.